Search Results

You are looking at 41 - 50 of 553 items for :

  • "pathology" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Leigh Selesner, Gabrielle Gauvin, Dorotea Mutabdzic, Eileen O’Halloran, Maxwell Kilcoyne, Kwan-Keat Ang, Jeffrey Farma, Elin Sigurdson, and Sanjay Reddy

. Diagnostic modality sensitivity and specificity were calculated by comparing findings on CT scan and DL to findings at the time of laparotomy and on final pathology. Specificity and sensitivity of the 2 modalities were compared using the McNemar Chi

Full access

Rachel L. Mitchell, Cory Kosche, Kelly Burgess, Shreya Wadhwa, Lela Buckingham, Ritu Ghai, Jacob Rotmensch, Oleksandra Klapko, and Lydia Usha

surgical debulking. Pathology was consistent with a high-grade serous carcinoma. Immunohistochemical staining was positive for TP53 ( Figure 2 ), WT-1, and ER. She received adjuvant chemotherapy with 6 cycles of carboplatin and paclitaxel. She remained

Full access

Laura J. Libby, Navneet Narula, Helen Fernandes, James F. Gruden, David J. Wolf, and Daniel M. Libby

Panel; Life Technologies, Inc., Grand Island, NY) showed that the patient harbored the KIT M541L variant in both the lymphangiomatosis and normal lung, suggesting the possibility of germline Figure 2. Surgical pathology. (A) Immunostain for D2

Full access

Christopher K. Bichakjian, Thomas Olencki, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Rachel Blitzblau, Glen M. Bowen, Carlo M. Contreras, Gregory A. Daniels, Roy Decker, Jeffrey M. Farma, Kris Fisher, Brian Gastman, Karthik Ghosh, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Manisha Loss, Daniel D. Lydiatt, Jane Messina, Kishwer S. Nehal, Paul Nghiem, Igor Puzanov, Chrysalyne D. Schmults, Ashok R. Shaha, Valencia Thomas, Yaohui G. Xu, John A. Zic, Karin G. Hoffmann, and Anita M. Engh

, 88 , 107 – 110 although a few studies have used other neuroendocrine markers. 111 Pathology Report Synoptic Reporting: Both historically and currently, consistent synoptic reporting of histopathologic parameters for MCCs is not widespread

Full access

George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg

diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach to care for patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and

Full access

Neha Mehta-Shah and Paola Ghione

opting for removal. Understanding who is at risk, recognizing the presenting features, and, when necessary, performing a thorough and expert pathology evaluation are essential to accurately diagnose BIA-ALCL or exclude the diagnosis as conclusively as

Full access

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell

influence the timing of chemotherapy initiation. These processes include referral from surgery to medical oncology, postoperative appointment scheduling, pathology turnaround time, and the role of additional testing, such as Oncotype DX (Genomic Health

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Lisa A. Gurski

laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform highly complex molecular pathology testing. 62 No specific testing methodology is recommended. 63 The three genes can be tested

Full access

John P. Sherbeck, Lili Zhao, and Richard W. Lieberman

The pathologic evaluation of lymph nodes (LNs) for metastatic disease plays an important role in the surgical staging of nearly all solid-organ malignancies. Nodal tissue is evaluated by pathology either as part of an en bloc resection or as

Full access

Nalan Nese, Ruta Gupta, Matthew H. T. Bui, and Mahul B. Amin

Edited by Kerrin G. Robinson

Novartis, Inc. References 1 Sesterhenn IA . Urothelial carcinoma in situ . In: Eble J Sauter G Epstein J Sesterhenn I , eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Urinary System and